Top

Published in:

Open Access 01-03-2017 | Laboratory Investigation

Shift of microRNA profile upon glioma cell migration using patient-derived spheroids and serum-free conditions

Published in: Journal of Neuro-Oncology | Issue 1/2017

Abstract

Glioblastoma multiforme (GBM) is the most frequent malignant primary brain tumor. A major reason for the overall median survival being only 14.6 months is migrating tumor cells left behind after surgery. Another major reason is tumor cells having a so-called cancer stem cell phenotype being therefore resistant towards traditional chemo- and radiotherapy. A group of novel molecular targets are microRNAs (miRNAs). MiRNAs are small non-coding RNAs exerting post-transcriptional regulation of gene expression. The aim of this study was to identify differentially expressed miRNAs in migrating GBM cells using serum-free stem cell conditions. We used patient-derived GBM spheroid cultures for a novel serum-free migration assay. MiRNA expression of migrating tumor cells isolated at maximum migration speed was compared with corresponding spheroids using an OpenArray Real-Time PCR System. The miRNA profiling revealed 30 miRNAs to be differentially expressed. In total 13 miRNAs were upregulated and 17 downregulated in migrating cells compared to corresponding spheroids. The three most deregulated miRNAs, miR-1227 (up-regulated), miR-32 (down-regulated) and miR-222 (down-regulated), were experimentally overexpressed. A non-significantly increased migration rate was observed after miR-1227 overexpression. A significantly reduced migration rate was observed after miR-32 and miR-222 overexpression. In conclusion a shift in microRNA profile upon glioma cell migration was identified using an assay avoiding serum-induced migration. Both the miRNA profiling and the functional validation suggested that miR-1227 may be associated with increased migration and miR-32 and miR-222 with decreased migration. These miRNAs may represent potential novel targets in migrating glioma cells.

Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352(10):987–996CrossRefPubMed

Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC et al (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10(5):459–466CrossRefPubMed

Giese A, Westphal M (1996) Glioma invasion in the central nervous system. Neurosurgery 39(2):235–250 (discussion 50–52).CrossRefPubMed

Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al (2006) Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444(7120):756–760CrossRefPubMed

Huang Z, Cheng L, Guryanova OA, Wu Q, Bao S (2010) Cancer stem cells in glioblastoma–molecular signaling and therapeutic targeting. Protein Cell. 2010;1(7):638–655.

Friedman RC, Farh KK, Burge CB, Bartel DP (2009) Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 19(1):92–105CrossRefPubMedPubMedCentral

Croce CM (2009) Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet 10(10):704–714CrossRefPubMedPubMedCentral

Hermansen SK, Kristensen BW (2013) MicroRNA biomarkers in glioblastoma. J Neurooncol 114(1):13–23CrossRefPubMed

Moller HG, Rasmussen AP, Andersen HH, Johnsen KB, Henriksen M, Duroux M (2013) A systematic review of microRNA in glioblastoma multiforme: micro-modulators in the mesenchymal mode of migration and invasion. Mol Neurobiol 47(1):131–144CrossRefPubMed

10.

Gabriely G, Yi M, Narayan RS, Niers JM, Wurdinger T, Imitola J et al (2011) Human glioma growth is controlled by microRNA-10b. Cancer Res 71(10):3563–3572CrossRefPubMedPubMedCentral

11.

Guessous F, Alvarado-Velez M, Marcinkiewicz L, Zhang Y, Kim J, Heister S et al (2013) Oncogenic effects of miR-10b in glioblastoma stem cells. Journal of Neuro-Oncol 112:153–163CrossRef

12.

Lin J, Teo S, Lam DH, Jeyaseelan K, Wang S (2012) MicroRNA-10b pleiotropically regulates invasion, angiogenicity and apoptosis of tumor cells resembling mesenchymal subtype of glioblastoma multiforme. Cell Death Dis 3:e398CrossRefPubMedPubMedCentral

13.

Sasayama T, Nishihara M, Kondoh T, Hosoda K, Kohmura E (2009) MicroRNA-10b is overexpressed in malignant glioma and associated with tumor invasive factors, uPAR and RhoC. Int J Cancer 125(6):1407–1413CrossRefPubMed

14.

Tosh D, Slack JM (2002) How cells change their phenotype. Nat Rev Mol Cell Biol 3(3):187–194CrossRefPubMed

15.

Toma JG, Akhavan M, Fernandes KJ, Barnabe-Heider F, Sadikot A, Kaplan DR et al (2001) Isolation of multipotent adult stem cells from the dermis of mammalian skin. Nat Cell Biol 3(9):778–784CrossRefPubMed

16.

Kondo T, Raff M (2000) Oligodendrocyte precursor cells reprogrammed to become multipotential CNS stem cells. Science 289(5485):1754–1757CrossRefPubMed

17.

Munthe S, Sorensen MD, Thomassen M, Burton M, Kruse TA, Lathia JD et al (2016) Migrating glioma cells express stem cell markers and give rise to new tumors upon xenografting. J Neuro-Oncol 130:53–62CrossRef

18.

Kolenda J, Jensen SS, Aaberg-Jessen C, Christensen K, Andersen C, Brunner N et al (2011) Effects of hypoxia on expression of a panel of stem cell and chemoresistance markers in glioblastoma-derived spheroids. J Neurooncol 103(1):43–58CrossRefPubMed

19.

Jensen SS, Aaberg-Jessen C, Andersen C, Schroder HD, Kristensen BW (2013) Glioma spheroids obtained via ultrasonic aspiration are viable and express stem cell markers: a new tissue resource for glioma research. Neurosurgery 73(5):868–886CrossRefPubMed

20.

Christensen K, Aaberg-Jessen C, Andersen C, Goplen D, Bjerkvig R, Kristensen BW (2010) Immunohistochemical expression of stem cell, endothelial cell, and chemosensitivity markers in primary glioma spheroids cultured in serum-containing and serum-free medium. Neurosurgery 66(5):933–947CrossRefPubMed

21.

https://tools.lifetechnologies.com/content/sfs/manuals/mp11490.pdf

22.

Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate—a practical and powerful approach to multiple testing. J R Stat Soc B 57(1):289–300

23.

Hou Z, Yin H, Chen C, Dai X, Li X, Liu B et al (2012) microRNA-146a targets the L1 cell adhesion molecule and suppresses the metastatic potential of gastric cancer. Mol Med Rep 6(3):501–506PubMed

24.

Gossen M, Freundlieb S, Bender G, Muller G, Hillen W, Bujard H (1995) Transcriptional activation by tetracyclines in mammalian cells. Science 268(5218):1766–1769CrossRefPubMed

25.

Gabriely G, Wurdinger T, Kesari S, Esau CC, Burchard J, Linsley PS et al (2008) MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol Cell Biol 28(17):5369–5380CrossRefPubMedPubMedCentral

26.

Halle B, Thisgaard H, Hvidsten S, Dam JH, Aaberg-Jessen C, Thykjaer AS et al (2015) Estimation of tumor volumes by [11C]MeAIB and [18F]FDG PET in an orthotopic glioblastoma rat model. J Nuclear Med 56:1562–1568CrossRef

27.

Yuan J, Xiao G, Peng G, Liu D, Wang Z, Liao Y et al (2015) MiRNA-125a-5p inhibits glioblastoma cell proliferation and promotes cell differentiation by targeting TAZ. Biochem Biophys Res Commun 457(2):171–176CrossRefPubMed

28.

Aldaz B, Sagardoy A, Nogueira L, Guruceaga E, Grande L, Huse JT et al (2013) Involvement of miRNAs in the differentiation of human glioblastoma multiforme stem-like cells. PloS one 8(10):e77098CrossRefPubMedPubMedCentral

29.

Aaberg-Jessen C, Norregaard A, Christensen K, Pedersen CB, Andersen C, Kristensen BW (2013) Invasion of primary glioma- and cell line-derived spheroids implanted into corticostriatal slice cultures. Int J Clin Exp Pathol 6(4):546–560PubMedPubMedCentral

30.

Jensen SS, Meyer M, Petterson SA, Halle B, Rosager AM, Aaberg-Jessen C et al (2016) Establishment and characterization of a tumor stem cell-based glioblastoma invasion model. PLoS ONE 11(7):e0159746CrossRefPubMedPubMedCentral

31.

Suh SS, Yoo JY, Nuovo GJ, Jeon YJ, Kim S, Lee TJ et al (2012) MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme. Proc Natl Acad Sci USA 109(14):5316–5321CrossRefPubMedPubMedCentral

32.

Yan SY, Chen MM, Li GM, Wang YQ, Fan JG (2015) MiR-32 induces cell proliferation, migration, and invasion in hepatocellular carcinoma by targeting PTEN. Tumour Biol 36(6):4747–4755CrossRefPubMed

33.

Wu W, Yang J, Feng X, Wang H, Ye S, Yang P et al (2013) MicroRNA-32 (miR-32) regulates phosphatase and tensin homologue (PTEN) expression and promotes growth, migration, and invasion in colorectal carcinoma cells. Mol Cancer 12:30CrossRefPubMedPubMedCentral

34.

Yang F, Wang W, Zhou C, Xi W, Yuan L, Chen X et al (2015) MiR-221/222 promote human glioma cell invasion and angiogenesis by targeting TIMP2. Tumour Biol 36(5):3763–3773CrossRefPubMed

35.

Zhang C, Zhang J, Hao J, Shi Z, Wang Y, Han L et al (2012) High level of miR-221/222 confers increased cell invasion and poor prognosis in glioma. J Transl Med 10:119CrossRefPubMedPubMedCentral

36.

Quintavalle C, Garofalo M, Zanca C, Romano G, Iaboni M, del Basso De Caro M et al (2012) miR-221/222 overexpession in human glioblastoma increases invasiveness by targeting the protein phosphate PTPmu. Oncogene 31(7):858–868CrossRefPubMed

37.

Hua Y, Larsen N, Kalyana-Sundaram S, Kjems J, Chinnaiyan AM, Peter ME (2013) miRConnect 2.0: identification of oncogenic, antagonistic miRNA families in three human cancers. BMC Genom 14:179CrossRef

38.

Henriksen M, Johnsen KB, Andersen HH, Pilgaard L, Duroux M (2014) MicroRNA expression signatures determine prognosis and survival in glioblastoma multiforme—a systematic overview. Mol Neurobiol 50(3):896–913CrossRefPubMedPubMedCentral

39.

Morello M, Minciacchi VR, de Candia P, Yang J, Posadas E, Kim H et al (2013) Large oncosomes mediate intercellular transfer of functional microRNA. Cell Cycle (Georgetown. Tex) 12(22):3526–3536CrossRef

40.

Sottoriva A, Spiteri I, Piccirillo SG, Touloumis A, Collins VP, Marioni JC et al (2013) Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci USA 110(10):4009–4014CrossRefPubMedPubMedCentral

41.

Verhaak RG, Hoadley KA, Purdom E, Wang V, Qi Y, Wilkerson MD et al (2010) Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 17(1):98–110CrossRefPubMedPubMedCentral

42.

Silber J, Jacobsen A, Ozawa T, Harinath G, Pedraza A, Sander C et al (2012) miR-34a repression in proneural malignant gliomas upregulates expression of its target PDGFRA and promotes tumorigenesis. PLoS ONE 7(3):e33844CrossRefPubMedPubMedCentral

43.

Mathew LK, Skuli N, Mucaj V, Lee SS, Zinn PO, Sathyan P et al (2014) miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma. Proc Natl Acad Sci USA 111(1):291–296CrossRefPubMed

Title: Shift of microRNA profile upon glioma cell migration using patient-derived spheroids and serum-free conditions
Publication date: 01-03-2017
Published in: Journal of Neuro-Oncology / Issue 1/2017
Print ISSN: 0167-594X
Electronic ISSN: 1573-7373
DOI: https://doi.org/10.1007/s11060-016-2356-x

At a glance: The STEP trials

Springer Medicine

Shift of microRNA profile upon glioma cell migration using patient-derived spheroids and serum-free conditions

Abstract

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2017

Assessment of vascularity in glioblastoma and its implications on patient outcomes

Atypical teratoid rhabdoid tumor in the first year of life: the Canadian ATRT registry experience and review of the literature

Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas

Patterns of care and treatment outcomes of patients with Craniopharyngioma in the national cancer database

The safety of resection for primary central nervous system lymphoma: a single institution retrospective analysis

The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial